Regulatory capture is a specific concept with a specific meaning. It does not require bribery, fraud, or explicit coordination. It describes a structural condition in which the regulatory apparatus governing an industry comes to serve the interests of that industry more reliably than it serves the public interest the apparatus was designed to protect. The mechanism is proximity, expertise asymmetry, and the slow drift of institutional priorities that comes when the regulated party is the most consistent, best-resourced, and most knowledgeable participant in the regulatory process.
The plasma industry offers a case study in how this works in practice — not through scandal, but through the ordinary operation of institutional relationships conducted over decades. The Plasma Protein Therapeutics Association, the industry's primary trade and lobbying body, has built a relationship with FDA, with Congress, and with the academic research infrastructure that makes it simultaneously the primary subject of regulation and the primary architect of the standards by which it is regulated.
This post maps that relationship. Not to allege corruption — the individuals involved are, in many cases, acting in good faith. But good faith is not the same as independence. And the question FSA asks is not whether people are corrupt. It is what the structure produces.
The most durable form of regulatory influence is not the kind that shows up in an investigation. It is the kind that becomes the standard. Once the industry's preferred framework is codified as regulation, the work of maintenance is invisible. The standard simply exists.
PPTA — the Plasma Protein Therapeutics Association — is the industry organization representing plasma collection companies and fractionators. Its members include CSL, Grifols, Takeda/BioLife, Octapharma, and Kedrion — the five firms that collectively control the vast majority of global plasma fractionation capacity. PPTA functions simultaneously as a lobbying organization, a standard-setting body, a research funder, and a liaison between the industry and its regulators.
The standard-setting function is the most structurally significant. PPTA operates the International Quality Plasma Program (IQPP), which establishes quality and safety standards for source plasma collection that supplement — and in practice, fill gaps in — FDA requirements. IQPP certification is effectively required for commercial viability: major fractionators will not accept plasma from non-IQPP-certified collection centers. This means the industry has created a private standard-setting architecture that operates alongside federal regulation, is controlled by the industry's own association, and shapes collection practices in ways that FDA oversight alone does not reach.
40+
Caucus Members
Congressional Plasma Caucus membership as of 2025, up from ~26–29 members. Bipartisan. Grown through PPTA fly-ins and Rayburn Building briefings.
IQPP
Private Standard
PPTA's International Quality Plasma Program — industry-controlled standard that supplements FDA regulation and effectively gates commercial access to fractionation markets.
QSEAL
Donor Standard
PPTA's donor center quality designation. Industry sets and enforces its own donor safety baseline — outside direct FDA authority, within the industry's institutional framework.
The central safety question underlying the blood economy is this: what are the long-term health effects of donating plasma up to 104 times per year? The FDA's frequency and volume limits are premised on the claim that this level of extraction is safe for healthy donors when monitored appropriately. That claim rests substantially on research. The question FSA asks is: who produced that research, and what did they stand to gain from its conclusions?
The answer is consistent. The major studies cited in defense of current FDA frequency limits are predominantly funded by PPTA member companies, conducted using methodologies the industry has advocated for, and published in journals where industry-academic collaboration in this field is standard. The methodology most commonly employed — the SF-36 self-reported health survey — measures how donors say they feel, not what longitudinal physiological data shows. Independent, long-term cohort studies with objective health outcomes are sparse. The evidentiary basis for FDA's safety framework is built primarily on research the industry paid for.
2023
High-frequency donor health outcomes. SF-36 survey across frequency groups. Finds no significant self-reported health differences vs. new donors. Published in Transfusion.
Self-report (SF-36). Cross-sectional. No independent physiological measurement. No long-term follow-up.
PPTA / Industry
2022
Immunoglobulin levels in frequent donors. Finds IgG recovery within acceptable range at FDA limits with adequate protein intake.
Controlled cohort. Protein monitoring. Industry-defined "acceptable range" as benchmark.
Industry
2024–25
Systematic review of plasma donation health impacts. Notes potential lasting effects on plasma proteins in high-frequency donors. Calls for more independent longitudinal data.
Literature review. Acknowledges gap in independent long-term cohort data. Finds evidence inconclusive.
Mixed / Academic
Ongoing
Long-term independent cohort study with objective physiological outcomes tracking bone density, immune function, protein levels over multi-year donation history.
Longitudinal. Objective measures. Independent of industry funding.
Independent
Limited — largely absent
2026
Canadian donor deaths at Grifols centers. NYT investigation raises questions about high-frequency safety protocols and adequacy of monitoring at maximum donation frequency.
Investigative journalism. Independent. Ongoing regulatory review in Canada.
Independent
The pattern is not exceptional. Industry-funded research is standard across pharmaceutical and medical device sectors. But it matters here in a specific way: the primary constituency whose interests are at stake — repeat donors, predominantly low-income — has no institutional voice in the research process. The industry funds the studies. The FDA reviews the studies. The donors are the subjects of the studies. They are not participants in designing them.
FSA Note · Insulation Maintenance
Self-reported health surveys are methodologically appropriate for certain research questions. They are not appropriate as the primary evidentiary basis for frequency limits governing a biological extraction performed on economically vulnerable populations up to 104 times annually. The choice to rely on self-report rather than objective longitudinal physiological data is not a neutral methodological decision. It is a choice that consistently produces favorable findings. The structure of the research mirrors the structure of the industry: both are optimized for supply continuity.
The Congressional Plasma Caucus is a bipartisan legislative working group dedicated to plasma supply issues. In 2025, PPTA and its member companies grew the caucus from approximately twenty-six to twenty-nine members to more than forty members — a significant institutional expansion achieved through a sustained engagement program including fly-in visits to Washington, briefings at the Rayburn House Office Building, and educational sessions connecting member company representatives with legislative staff and members of Congress.
The caucus is not a corrupt institution. Congressional caucuses are a normal feature of the legislative landscape — there are caucuses for every industry, interest group, and constituency. But the caucus performs a specific function in the blood economy's insulation architecture: it converts supply chain arguments into political ones, building a constituency of legislators whose engagement with plasma policy is mediated entirely by the industry that organized the caucus and populated its briefings.
Growth driven by PPTA fly-in program, Rayburn Building briefings (July 2025), and member company constituent engagement. Bipartisan. Patient access framing central to outreach.
The briefing content presented to caucus members and their staff is produced by the industry. Patient access arguments — the genuine reality that disrupting plasma supply harms people who depend on immunoglobulin therapy — are prominently featured. The labor economics of the donor base, the siting methodology, the self-reported safety data, and the border visa litigation are not the frame through which legislators encounter plasma policy. The caucus mediates the frame.
PPTA's relationship with FDA is formally collaborative. The association participates in FDA's Center for Biologics Evaluation and Research (CBER) liaison meetings, contributes to guidance document development, submits comments on proposed rules, and provides data used in regulatory assessments. This is not unusual — regulated industries routinely engage with their regulators. The FDA actively seeks industry input because industry possesses technical knowledge that the agency, with its limited resources, cannot independently generate.
The asymmetry this creates is structural. FDA's career staff in biologics regulation number in the hundreds. PPTA's member companies collectively employ thousands of technical and regulatory affairs professionals whose full-time work is understanding and shaping the regulatory environment. When FDA develops guidance on donor frequency limits, protein monitoring protocols, or deferral criteria, the most technically sophisticated input it receives comes from the industry whose business model depends on the outcome of that guidance.
CBER Liaison Meetings
Formal PPTA–FDA liaison process. Regular meetings between association staff and CBER officials. Industry presents safety data, operational concerns, and guidance requests. FDA receives technical input it lacks resources to generate independently.
Shapes guidance before it is drafted. Industry frames the problem and provides the evidence base simultaneously.
IQPP / QSEAL Standards
Industry-operated private standard that supplements FDA requirements. IQPP certification effectively required for commercial viability. Sets donor screening, volume, and monitoring practices. FDA accepts IQPP compliance as evidence of good practice.
Industry self-regulates in gaps between formal FDA rules. Regulatory floor defined by PPTA, not solely by FDA.
Funded Safety Studies
PPTA member companies fund research on donor health outcomes. Studies use industry-preferred methodology (SF-36 self-report). Results consistently support current frequency limits. Published in peer-reviewed journals.
Evidence base for FDA safety framework is built primarily by the party whose business model benefits from permissive limits.
Guidance Comment Process
When FDA proposes guidance changes, PPTA submits formal comments. Industry comments are technically detailed, extensively documented, and represent the most sophisticated input FDA receives on most plasma-related guidance.
Industry expertise asymmetry means industry comments disproportionately shape final guidance language.
Congressional Caucus
Bipartisan caucus grown to 40+ members through PPTA fly-in program. Briefed on patient access, supply chain, and safety using industry-produced materials. Creates legislative constituency that opposes supply-restricting regulation.
Political insulation. Converts supply economics into congressional advocacy. Complicates any FDA move toward stricter limits.
Tariff and Trade Advocacy
In 2025, PPTA actively lobbied for tariff exemptions on plasma-related inputs and cross-border supply protection. International trade policy framed as patient access issue.
Expands industry insulation into trade and foreign policy domains. Patient access argument mobilized to protect commercial supply chains.
What does a congressional briefing on plasma policy look like? The following is a composite representation, drawn from publicly available PPTA advocacy materials, congressional testimony records, and industry communications. It illustrates the framing through which legislators encounter the blood economy's architecture.
The United States is the world's leading supplier of plasma-derived medicines, providing approximately 70% of the global supply of immunoglobulins, clotting factors, and albumin. These medicines are essential for patients with primary immunodeficiency, hemophilia, and other serious conditions for which no alternative treatment exists.
American plasma donors — who voluntarily choose to donate and are compensated for their time — make this life-saving supply possible. The US system is the most regulated and rigorously screened in the world. FDA's Center for Biologics Evaluation and Research maintains comprehensive oversight of collection, testing, and manufacturing.
Any disruption to the US plasma supply — whether through regulatory changes, trade restrictions, or border policy — would have immediate and serious consequences for patients who depend on these medicines. The Congressional Plasma Caucus plays a vital role in ensuring that policymakers understand the stakes of plasma supply policy decisions.
[Composite · Illustrative · Drawn from public PPTA advocacy materials and congressional testimony record]
FSA Analysis: Trium Publishing House · The Blood Economy · Post V
Every sentence in that document is defensible. The US does supply seventy percent of global plasma. The medicines are essential. The donors are not legally coerced. The system is regulated. Patient harm from supply disruption is a real risk.
What the document does not contain: the siting methodology, the poverty demographics, the self-report evidentiary basis for safety limits, the border visa litigation, the margin structure, or any acknowledgment that the industry wrote the document being used to shape the policy that governs it. The insulation layer, in its most refined form, is simply an accurate description of some things, in a frame that makes other things invisible.
Regulatory capture does not require anyone to act in bad faith. FDA officials who accept PPTA-funded research as the evidentiary basis for safety guidance are not corrupt — they are using the best available data in a resource-constrained environment. Congressional staff who attend PPTA briefings and form views about plasma policy are not corrupt — they are doing their jobs with the information available to them. PPTA representatives who present their industry's case effectively are not corrupt — they are performing the function trade associations are designed to perform.
What the structure produces, through the aggregate operation of these individually defensible actions, is a regulatory environment in which the primary beneficiary of permissive standards is also the primary participant in setting those standards, the primary funder of the research that validates them, and the primary organizer of the political constituency that defends them against challenge. The donor — who bears the physical cost of those standards and has no institutional seat at any of these tables — is represented in the process only by the industry that depends on their continued participation.
Post VI will move from domestic institutional architecture to international moral posture. The European nations that prohibit paid plasma domestically while importing it from the United States have built their own insulation layer — one that allows the ethical critique of the American system to coexist with absolute dependency on its output.
Next · Post VI · The European Alibi — EU prohibition as moral insulation for importing nations. The ethics are domestic. The dependency is global.
Posts
